Emergent BioSolutions Inc. 8-K

What Happened
Emergent BioSolutions (through subsidiary Emergent Product Development Gaithersburg Inc.) announced on June 29, 2026 that the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) exercised Option Year 7 under Emergent’s 10‑year ACAM2000 contract via Modification No. 15. The modification is valued at $52.7 million and requires delivery of ACAM2000® doses, ancillaries and diluent replacement lots in June 2026, with any remaining diluent deliveries by December 2026. The company issued a press release the same day (furnished as Exhibit 99.1).

Key Details

• Modification No. 15: Option Year 7 exercised under the existing 10‑year ACAM2000 contract with ASPR.
• Value: $52.7 million.
• Delivery schedule: vaccine doses, ancillaries and diluent replacement lots due June 2026; remaining diluent by December 2026.
• Filing: 8‑K dated June 29, 2026; full text of Modification No. 15 to be filed as an exhibit in the next Form 10‑Q.

Why It Matters
This is a material government order under Emergent’s long‑term ACAM2000 supply contract and represents near‑term, contract‑backed revenue of $52.7M tied to deliveries in 2026. For investors, the announcement confirms continued government demand and firm delivery obligations that will influence Emergent’s product shipment and revenue timing for the remainder of 2026.